Alogliptin benzoate, the benzoic acid salt of the DPP-4 inhibitor alogliptin, is specified in downstream pharmaceutical manufacturing as a crystalline active pharmaceutical ingredient. The stoichiometric salt conversion factor is 1.360 based on a free base molecular weight of 339.39 g/mol and a salt molecular weight of 461.51 g/mol; therefore a 6.25 mg alogliptin free base dose corresponds to 8.5 mg alogliptin benzoate, 12.5 mg to 17.0 mg, and 25 mg to 34.0 mg. The downstream scenarios below are limited to pharmaceutical manufacturing routes in which the API is converted into oral solid dosage forms or used in investigational parenteral preparation. The API is manufactured under ICH Q7 and released according to specifications aligned with ICH Q6A, ICH Q3A, ICH Q3C, and ICH Q3D. Residual solvent limits follow ICH Q3C; where applicable, Class 1 benzene is limited to 2 ppm, Class 2 methylene chloride to 600 ppm, and Class 3 ethanol to 5000 ppm. Elemental impurity limits are route-dependent because oral and parenteral permitted daily exposure values differ under ICH Q3D.

What Blend Segregation Mechanisms Emerge in Low-Dose Direct Compression of Alogliptin Benzoate?

Direct compression of alogliptin benzoate at free-base equivalents of 6.25 mg, 12.5 mg, and 25 mg per tablet places only 8.5 mg, 17.0 mg, and 34.0 mg of salt in each die cavity. In a 200 mg total core weight, the active salt occupies 4.25% w/w, 8.50% w/w, and 17.0% w/w, creating a low-dose drug content range in which hopper-induced segregation and lubricant agglomeration become the primary content-uniformity risks. Industry compliance for this scenario is governed by 21 CFR 211.110 in-process testing, USP 905 uniformity of dosage units, USP 711 dissolution, USP 701 disintegration, and ICH Q6A specification-setting. The formulation and API must also comply with ICH Q3A for degradation products, ICH Q3C for residual solvents, and ICH Q3D for elemental impurities. Process design begins with geometric dilution or trituration of alogliptin benzoate with a diluent having a matched particle size distribution; blend uniformity is sampled at 10–20 locations in a low-shear tumble blender and should demonstrate a relative standard deviation below 5% before compression. The blend is transferred to a rotary tablet press equipped with a paddle force feeder; eccentric single-station presses are considered unsuitable for an 8.5 mg salt dose because of die-fill variability. Precompression and main compression forces are selected during development; representative low-dose formulations are often compressed at main compression forces of 8–15 kN on 9 mm biconvex tooling, but the final force must be justified by tensile strength, friability, and ejection force data. Lubrication with magnesium stearate is limited to 0.5–1.5% w/w with a controlled post-lubrication mixing time; over-lubrication increases disintegration time and reduces tablet hardness. If ambient relative humidity exceeds 60%, pre-drying of hygroscopic excipients is required, and alogliptin benzoate should remain in sealed containers until use. Salt disproportionation risk in acidic microenvironments should be screened under 40°C/75% RH for 4 weeks with PXRD and HPLC purity; published data for this specific alogliptin benzoate grade is limited. The terminal product is an immediate-release film-coated tablet containing 6.25 mg, 12.5 mg, or 25 mg alogliptin free base equivalent.

For fixed-dose combination with metformin HCl, the marketed strength pairing combines alogliptin free base 12.5 mg with metformin HCl 500 mg or 1000 mg; the corresponding alogliptin benzoate salt mass is 17.0 mg per tablet. This places the alogliptin salt at approximately 1.7% w/w in a 1000 mg metformin-containing tablet core, creating a two-component process in which the high-dose metformin HCl dominates granulation behavior while the low-dose alogliptin benzoate controls blend uniformity risk. The industry compliance framework includes 21 CFR 211.110, USP 905, USP 711, ICH Q3A/Q3C/Q3D, 21 CFR 320 for any bioequivalence requirement, and a nitrosamine impurity assessment under ICH M7 and regional metformin-specific guidance; for NDMA, the published acceptable intake limit of 96 ng/day must be applied. The downstream process for this fixed-dose combination typically separates metformin HCl wet granulation from alogliptin benzoate addition. Metformin HCl, which is poorly compressible and hygroscopic, is granulated in a high-shear granulator with a povidone binder solution; the granulation is dried in a fluid-bed dryer until a moisture specification is achieved, then milled through an oscillating sieve. Alogliptin benzoate is preblended with microcrystalline cellulose and crospovidone in an external dry phase and added to the milled metformin granules. This two-phase process reduces direct aqueous exposure of alogliptin benzoate and limits stratification in the hopper. Production-scale failures in this configuration include content uniformity drift on rotary tablet presses with force feeders when the external alogliptin preblend is not adequately bonded to the metformin granule surface or when the forced feeder is operated too aggressively. The formulation addition ratio must be adjusted after granule yield: if the granulated metformin fraction contains moisture or particle agglomerates, final blend sampling must confirm that the alogliptin benzoate remains at 17.0 mg per tablet within USP 905 acceptance criteria. The terminal product is a film-coated immediate-release fixed-dose combination tablet containing alogliptin 12.5 mg and metformin HCl 500 mg or 1000 mg.

Low-Dose Dual-Active Direct Compression Window for Alogliptin Benzoate with Pioglitazone HCl

A fixed-dose combination with pioglitazone HCl uses alogliptin free base 25 mg with pioglitazone HCl 15 mg, 30 mg, or 45 mg; the alogliptin benzoate salt equivalent is 34.0 mg per tablet. If the total core weight is 300 mg, the alogliptin benzoate loading is 11.3% w/w and the combined active loading remains low enough for direct compression or dry granulation. The relevant industry compliance standards are USP 905 for content uniformity, USP 711 for dissolution, ICH Q6A for specifications, ICH Q3A/Q3C/Q3D for impurities, and 21 CFR 320 for any fixed-dose combination bioavailability requirement. The manufacturing process must address triboelectric charging differences between the two crystalline actives. At low ambient humidity, interparticulate charging can produce hopper layering and dose weight fluctuation. A humidity-controlled blending room at 35–45% RH, a low-shear blender with conductive grounding, and a rotary tablet press with force feeder are the minimum equipment set. If the blend RSD exceeds 4% during development sampling, roller compaction should replace direct compression. For roller-compacted material, the granules are milled to a particle size that passes a 0.8–1.2 mm sieve and reblended with extragranular disintegrant and lubricant. Tablets are compressed to a hardness that maintains friability below 1.0% under Ph. Eur. 2.9.7. The terminal product is a film-coated immediate-release tablet containing alogliptin 25 mg and pioglitazone HCl 15 mg, 30 mg, or 45 mg.

When Roller-Compacted Granules Bridge Capsule Fill and Immediate-Release Granule Forms

This route is used when alogliptin benzoate is converted into a granule intermediate for hard capsule filling, sachet filling, or subsequent tablet compression. The addition ratio is expressed as drug content per gram of granule mass rather than per single unit; for example, a granule matrix with 8.5 mg alogliptin benzoate per 1.0 g of granules contains 0.85% w/w active salt. The relevant compliance specifications are ICH Q6A for particle size distribution, USP 711 dissolution, USP 905 uniformity of dosage units when filled into sachets, and ICH Q3A/Q3C/Q3D for impurities. Granule particle-size distribution is measured by sieve analysis according to Ph. Eur. 2.9.38; the fines fraction must be controlled because excess fines can arrest flow from the hopper of a dosator-type capsule filler. The manufacturing process uses a dry granulation line: alogliptin benzoate is preblended with a diluent such as microcrystalline cellulose and a dry binder, passed through a roller compactor, and milled through an oscillating sieve with a 0.8–1.5 mm screen. The granules are then passed through a tumble blender, sampled for blend uniformity, and filled into hard gelatin or HPMC capsules or sealed into bulk sachet containers. At production scale, the primary batch-to-batch variance is granule bulk density shift caused by incoming alogliptin benzoate particle size distribution; if bulk density changes by more than 5%, the dosator fill weight must be adjusted to keep the delivered salt mass within USP 905 limits. Aqueous wet granulation is not the primary route; if wet granulation is considered, salt disproportionation and degradation should be screened under 40°C/75% RH before scale-up. The terminal product in this scenario is either a granule-filled hard capsule containing alogliptin free base equivalents of 6.25 mg, 12.5 mg, or 25 mg, or a single-dose sachet granule; no commercially approved alogliptin granule sachet is referenced in US or EU labels, so the sachet presentation is classified as a development-led downstream use.

When a hard gelatin capsule is selected for low-dose alogliptin benzoate without prior granulation, the process window becomes narrower because direct powder filling is sensitive to blend bulk density and particle cohesion. The addition ratio follows the same salt equivalents of 8.5 mg, 17.0 mg, and 34.0 mg per capsule; at a total fill weight of 150 mg, the active salt loading ranges from 5.7% w/w to 22.7% w/w. Industry compliance includes USP 905, USP 711, ICH Q6A, and 21 CFR 211.110. The downstream process requires a low-speed tamping-type or dosator-type capsule filler with tight fill weight control; alogliptin benzoate should be preblended with a free-flowing diluent and trituration steps to avoid dose drift. The terminal product is a hard gelatin or HPMC capsule containing alogliptin free base equivalents of 6.25 mg, 12.5 mg, or 25 mg; this presentation is primarily used for clinical trial material or patient-specific compounding, and stability data must be generated by the applicant.

Published data for injectable alogliptin benzoate formulations is limited; no parenteral alogliptin product is approved in the US, EU, or Japan. Injectable development therefore requires primary pharmaceutical development rather than reliance on a compendial precedential formulation. The relevant compliance standards for parenteral feasibility screening are USP 1, USP 85, USP 788, EU GMP Annex 1, ISO 14644-1, ICH Q3D parenteral permitted daily exposure values, ICH Q1A/R2, and ICH Q8/Q9/Q10. No approved or compendial addition ratio exists; any target concentration must be based on primary solubility, tonicity, and pH stability data. The downstream process, if feasibility is established, would involve dissolution in water-for-injection, pH adjustment, sterile filtration through a 0.22 µm membrane, aseptic filling, and possibly lyophilisation using a collapse temperature determined by differential scanning calorimetry. Terminal steam sterilisation is acceptable only if forced degradation data under ICH Q1A demonstrate no unacceptable degradation. The terminal product in this scenario is an investigational injectable solution or lyophilised powder; this statement does not imply injectable approval or clinical benefit.